Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of MOLN.SW is 9.2 and suggests 203% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell